Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2842438 | 1.00 | GRM5 (0.43) | GRM5LMNAHSD17B10KDM4ETSHR | |
| SCHEMBL1899368 | 0.85 | GRM5 (0.49) | GRM5 | |
| SCHEMBL3276812 | 0.85 | GRM5 (0.49) | GRM5 | |
| SCHEMBL2838365 | 0.84 | GRM5 (0.43) | GRM5 | |
| SCHEMBL2841216 | 0.84 | GRM5 (0.43) | GRM5 | |
| SCHEMBL992597 | 0.81 | GRM5 (0.46) | GRM5LMNAHSD17B10KDM4ETSHR | |
| SCHEMBL991485 | 0.81 | GRM5 (0.46) | GRM5LMNAHSD17B10KDM4ETSHR | |
| SCHEMBL3802097 | 0.79 | GRM5 (0.42) | GRM5 | |
| SCHEMBL14734735 | 0.77 | GRM5 (0.44) | GRM5MAPT | |
| SCHEMBL5119344 | 0.76 | LMNA (0.54) | GRM5LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272929-A1 | ORGANIC COMPOUNDS | UMBRICHT DANIEL (CH) | 2015-10-01 | — | — | US | disclosed |
| EP-2826478-A1 | COMBINATIONS COMPRISING MGLUR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-20140194423-A1 | COMBINATION PRODUCTS | GOMEZ-MANCILLA BALTAZAR (CH) | 2014-07-10 | — | — | US | disclosed |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8703809-B2 | Combination products | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| WO-2013131981-A1 | PREDICTIVE MARKERS USEFUL IN THE DIAGNOSIS AND TREATMENT OF FRAGILE X SYNDROME (FXS) | NOVARTIS AG (CH) | 2013-09-12 | — | — | WO | disclosed |
| EP-2563934-A1 | PREDICTIVE MARKERS USEFUL IN THE TREATMENT OF FRAGILE X SYNDROME (FXS) | Novartis AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-20130052644-A1 | Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS) | NOVARTIS AG (CH) | 2013-02-28 | — | — | US | disclosed |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120122878-A1 | COMBINATION PRODUCTS | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20100249136-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-30 | — | — | US | disclosed |
| EP-2211859-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | RALF GLATTHAR | 2010-02-18 | — | — | US | disclosed |
| WO-2010000763-A2 | COMBINATION PRODUCTS | NOVARTIS AG (CH) | 2010-01-07 | — | — | WO | disclosed |
| EP-2069305-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009047296-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OP PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047303-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008031550-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTANATE RECEPTORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | GRM5 1/4885LMNA 4734/4885HSD17B10 2546/4885 |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885LMNA 4712/4885HSD17B10 2492/4885 |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885LMNA 4712/4885HSD17B10 2492/4885 |
| US-20120122878-A1 | COMBINATION PRODUCTS | GRM5, GRM2, GRM1 | GRM5 1/4885LMNA 4872/4885HSD17B10 1395/4885 |
| US-20150272929-A1 | ORGANIC COMPOUNDS | GRM5, GRM2, GRM4 | GRM5 1/4885LMNA 4714/4885HSD17B10 2550/4885 |
| US-20140194423-A1 | COMBINATION PRODUCTS | GRM5, GRM2, GRM1 | GRM5 1/4885LMNA 4872/4885HSD17B10 1395/4885 |
| US-20100249136-A1 | ORGANIC COMPOUNDS | GRM5, GRM2, GRM4 | GRM5 1/4885LMNA 4714/4885HSD17B10 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.